Peter J. Pitts - 24 Jul 2026 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: Executive Chairman, Director
Issuer ticker: BCLI
Reported as of: 24 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2026, 17:00:07 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter J. Pitts

Key filing fact

Peter J. Pitts filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 28 Jul 2026.

Key facts

This page summarizes Peter J. Pitts's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jul 2026, 17:00.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002138486 Primary reporting owner

Pitts Peter Joe

Relationship: Executive Chairman, Director
Address: C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FLOOR, NEW YORK
Signature: /s/ Peter J. Pitts
Signature date: 28 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCLI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +900,000
Change %
Price: $0.000000^*
Shares after: 900,000
Date: 24 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 900,000
Exercise price: $1.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

Footnote F2

The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.